HarbourVest Partners Invests $21 Million in Post-IPO Drug Developer Generate Biomedicines

On May 15, 2026, HarbourVest Partners disclosed a new investment of approximately $21 million into Generate Biomedicines (NASDAQ:GENB), acquiring over 1.7 million shares during the first quarter of 2026. The position now represents about 21% of the fund's reportable assets under management and highlights confidence in the post-IPO biotech firm.

By Jonathan Ponciano, The Motley Fool Sun, May 31, 2026 at 11:37 PM GMT+3 4 min read · Yahoo Finance · May 31, 2026, 20:37 UTC

Tickers: $GENB

Topics: biotech institutional_investment post-ipo

Read the full article at Yahoo Finance

More World news

Donald Trump Suggests Tim Cook as Potential Successor for Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 16:09 UTC
Yankees President Randy Levine Advocates for Protect College Sports Act and Addresses MLB Labor Uncertainty CNBC · November 12, 2026, 15:34 UTC
Donald Trump Suggests Apple Chairman Tim Cook as Potential Successor to Nvidia CEO Jensen Huang TechCrunch · November 12, 2026, 16:12 UTC
Bybit Announces Title Partnership for Inaugural Stockholm Open ATP 250 Tournament PR Newswire · November 12, 2026, 16:11 UTC
SES AI Reports Q3 2026 Revenue Growth Amid Strategic Shift Toward Drone Battery Market Motley Fool · November 12, 2026, 16:10 UTC
Nvidia Shares Decline Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 16:07 UTC
Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC